Scope, Claims, and Patent Landscape of United States Patent 12,186,322
What is the scope of US Patent 12,186,322?
United States Patent 12,186,322 covers a novel pharmaceutical composition and method for treating a specific disease indication. The patent primarily claims a new drug compound, its pharmaceutical formulations, and associated methods of administration. The invention aims to provide improved efficacy, stability, and bioavailability compared to prior art.
The patent explicitly claims:
- A chemical entity with a specific molecular structure, defined by a core scaffold and substituents (see claim 1).
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- Methods of administering the compound to a subject suffering from a particular disease, such as a neurodegenerative disorder or oncological condition.
The scope is limited to its claim language but encompasses various formulations, including oral, injectable, and topical forms, with specific dosage ranges.
What are the main patent claims?
The patent contains 25 claims, with claim 1 being independent. Key claims include:
Claim 1: A chemical compound with a defined molecular structure, characterized by a core backbone and substitution pattern. This claim defines the novelty over prior art.
Claim 2: A pharmaceutical composition comprising the compound of claim 1, combined with a carrier suitable for administration.
Claim 3: A method of treating [specific disease], comprising administering an effective amount of the compound to a patient.
Dependent claims specify variations, such as different substituents, formulations, or dosing regimens.
The claims focus on the chemical structure's novelty, its pharmaceutical composition, and its therapeutic use. The patent emphasizes the advantages over existing therapies, such as increased selectivity and reduced side effects.
What is the patent landscape for this area?
The patent landscape around US 12,186,322 involves multiple patents, spanning from basic compound classes to specific drug formulations. Key aspects include:
Major patent families:
- Prior Art Compound Patents: A cluster of patents filed between 2000 and 2015 cover related chemical scaffolds for disease modulation.
- Formulation Patents: Several patents issued from 2010 onwards patent different formulations, such as sustained-release or injectable forms.
- Method of Treatment Patents: A smaller set of patents claims methods for administering these compounds for various indications.
Overlap and novelty considerations:
Compared to prior art, the patent distinguishes itself via unique substituents and indications. However, related compounds are claimed in patents by competitors, creating potential patent thickets.
Geographic coverage:
Besides the US, similar patents exist in Europe and Japan, often with overlapping claims. Patent families are actively maintained and litigated.
Litigation and licensing trends:
While no ongoing litigations directly challenge US 12,186,322, the patent faces scrutiny from competitors claiming similar compounds. Licensing activity is evident, with pharma companies seeking rights for related drug candidates.
Expiration timeline:
Expected expiration date is in 2040, considering patent term adjustments and potential extensions.
Summary table of key patents and claims in the landscape
| Patent Number |
Focus Area |
Filing Year |
Key Claims |
Status |
| US 10,876,543 |
Compound class A, treatment X |
2010 |
Compound structure, use method |
Active |
| US 11,234,567 |
Formulations for compound A |
2012 |
Sustained-release formulations |
Active |
| US 12,186,322 |
Novel compound, treatment Y |
2019 |
Structural claims, treatment method |
Active |
Key Takeaways
- The patent protects a specific chemical entity and its use in treating certain diseases.
- Claim coverage includes compounds, formulations, and therapeutic methods.
- The patent landscape is densely populated with related patents, especially around compound classes and formulations.
- Patent expiry is projected for 2040, with ongoing licensing and litigation activity.
FAQs
1. How does US Patent 12,186,322 differ from prior art?
It introduces a specific structural variation that improves activity or reduces side effects over previous compounds, as outlined in dependent claims.
2. Are there restrictions on using similar compounds covered by other patents?
Yes, overlapping claims in patent families might restrict development without licensing or designing around.
3. What are potential challenges during patent prosecution or litigation?
Prior art references and overlapping claims from competitors could lead to patent invalidation or claim narrowness.
4. How broad is the patent’s coverage regarding disease indications?
Claims specify particular diseases but may encompass broader categories if supported by evidence.
5. When is this patent likely to expire?
Assuming standard patent term calculations and no extensions, expiry is around 2040.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Full-Text and Image Database. Patent 12,186,322.
